Fesia Technology

Fesia operates in neurorehabilitation medical devices, focusing on functional electrical stimulation rather than conventional braces or passive supports. Its portfolio addresses both upper- and lower-limb impairment: Fesia Walk and Fesia Walk Assistive target foot drop and walking, while Fesia Grasp targets wrist and finger movement. Fesia Bike Pro Active and related products extend the application into cycling-assisted therapy. The acquisition by Ottobock is strategically important because it connects Fesia’s multifield stimulation approach with a global orthotics and mobility-device business. Compared with providers centered primarily on mechanical orthoses, Fesia emphasizes programmable electrical stimulation and rehabilitation use cases across stroke, spinal cord injury, cerebral palsy, multiple sclerosis, and other neurological conditions. Its competitive constraints are also visible: the company has a relatively small employee band of 11–50 people, limited disclosed funding, and no publicly disclosed valuation. Differentiation therefore rests on clinical applicability, product breadth, and integration potential within Ottobock.

Fesia’s trajectory shows a progression from early-stage technology development to commercial neurorehabilitation products and, ultimately, strategic acquisition. The company was founded in 2016 and received a seed investment from BIC Gipuzkoa Berrilan in 2017. In 2018, it secured an €71,429 grant from EISMEA and publicly announced an €800,000 investment round intended to support two rehabilitation devices. The 2019 equity crowdfunding round raised €772,185, bringing disclosed total funding to $959,123 on a converted basis. Product development expanded from Fesia Walk for foot drop into Fesia Grasp for hand rehabilitation, Fesia Walk Assistive for personal use, Fesia Clinic services, and an SDK for external development and robotics applications. The Jul 7, 2026 acquisition by Ottobock is the clearest inflection point: it may provide distribution, manufacturing, regulatory, and commercial resources that would be difficult for a small independent company to build alone. However, employee growth, revenue, clinical adoption, and post-acquisition milestones are not publicly disclosed, so the scale and pace of future expansion cannot yet be assessed.